Drug intelligence / Profile preview

PF1807

Development stage: Preclinical
Lead developer: ImmunoForge
Modality: Peptides, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

PF1807 is a long-acting biologic therapy being developed by ImmunoForge for the treatment of sarcopenia. It is a glucagon-like peptide-1 receptor (GLP-1R) agonist that utilizes ImmunoForge's proprietary Elastin-Like Polypeptide (ELP) fusion platform technology. This platform extends the half-life of the peptide, enabling a once-monthly dosing schedule. By targeting the GLP-1 receptor, PF1807 aims to address muscle loss and functional decline associated with sarcopenia. ImmunoForge is positioning this asset as a monthly therapy to improve patient compliance and therapeutic outcomes in muscular diseases.

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on PF1807.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF1807.

Explore the full profile